Exploration of Practical Biomarkers for Systemic Drug Therapy for Hepatocellular Carcinoma DOI Open Access
Kenta Motomura, Akifumi Kuwano, Masatake Tanaka

et al.

Published: July 17, 2023

A number of agents, including immune checkpoint inhibitors, have become available for the treatment hepatocellular carcinoma (HCC). However, objective response rate these drugs is currently only 30% to 40%, with a high incidence side effects. There are also no prac-tical biomarkers predict their therapeutic Most systemic therapies HCC performed in general hospitals without research facilities. Such can perform imaging tests, like CT and MRI, as well pathological diagnosis using tumor tissue sampling im-munohistochemical staining. analyzing genomic or transcriptomic profiles difficult because limitations facilities, personnel, cost. Therefore, this review, we provide an overview wide range that has been conducted on from blood, tissue, information be used practically predicting effect before begins. For hos-pitals treat patients, recommend conducting after assessing state within much possible by collecting blood samples per-forming pre- MRI image evaluations.

Language: Английский

MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options DOI Creative Commons

Yuming Shi,

Erfan Taherifard, A.I. Saeed

et al.

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(6), P. 5965 - 5983

Published: June 13, 2024

Hepatocellular carcinoma (HCC) represents a significant burden on global healthcare systems due to its considerable incidence and mortality rates. Recent trends indicate an increase in the worldwide of metabolic dysfunction-associated steatotic liver disease (MASLD) shift etiology HCC, with MASLD replacing hepatitis B virus as primary contributor new cases HCC. MASLD-related HCC exhibits distinct characteristics compared viral including unique immune cell profiles resulting overall more immunosuppressive or exhausted tumor microenvironment. Furthermore, is frequently identified older age groups among individuals cardiometabolic comorbidities. Additionally, greater percentage occur noncirrhotic patients those etiologies, hindering early detection. However, current clinical practice guidelines lack specific recommendations for screening patients. The evolving landscape management offers spectrum therapeutic options, ranging from surgical interventions locoregional therapies systemic treatments, across various stages disease. Despite ongoing debates, evidence does not support differences optimal treatment modalities based etiology. In this study, we aimed provide comprehensive overview literature trends, characteristics, implications,

Language: Английский

Citations

6
Exploration of Practical Biomarkers for Systemic Drug Therapy for Hepatocellular Carcinoma DOI Open Access
Kenta Motomura, Akifumi Kuwano, Masatake Tanaka

et al.

Published: July 17, 2023

A number of agents, including immune checkpoint inhibitors, have become available for the treatment hepatocellular carcinoma (HCC). However, objective response rate these drugs is currently only 30% to 40%, with a high incidence side effects. There are also no prac-tical biomarkers predict their therapeutic Most systemic therapies HCC performed in general hospitals without research facilities. Such can perform imaging tests, like CT and MRI, as well pathological diagnosis using tumor tissue sampling im-munohistochemical staining. analyzing genomic or transcriptomic profiles difficult because limitations facilities, personnel, cost. Therefore, this review, we provide an overview wide range that has been conducted on from blood, tissue, information be used practically predicting effect before begins. For hos-pitals treat patients, recommend conducting after assessing state within much possible by collecting blood samples per-forming pre- MRI image evaluations.

Language: Английский

Citations

2